NAGE Niagen Bioscience Inc
USHealthcareAs of 2026-08-24
Why NAGE matters now
Niagen Bioscience Inc (NAGE) is a US stock in Healthcare. The latest InvestLog snapshot shows $3.21 with +0.00% on the session and $255.7M in market capitalization; recent performance reads 1-month -4.63% and YTD -44.97%.
The latest financial table shown here is Q1 2026, with revenue of $31.5M, net income of $6.3M, and EPS of $0.07. Investors can compare that operating picture with valuation signals such as P/E 20.59 and FCF yield 1.5%.
The latest indexable market news headline is "Niagen Bioscience Expands Tru Niagen® Retail Footprint with GNC and Sam's Club" from GuruFocus.
Additional event context on this page matters because analyst consensus is Buy with a median target of $10.50; recent insider activity includes Fried Robert N filing M-Exempt. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
20.59
PEG
0.20
P/B
3.40
P/S
2.14
EV/EBITDA
10.04
DCF Value
$-1.52
FCF Yield
1.5%
Div Yield
0.0%
Margins & Returns
Gross Margin
64.3%
Operating Margin
8.5%
Net Margin
14.3%
ROE
25.4%
ROA
16.3%
ROIC
11.4%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $31.5M | $6.3M | $0.07 |
| Q4 2025 | $33.8M | $4.1M | $0.05 |
| FY 2025 | $129.4M | $17.4M | $0.20 |
| Q3 2025 | $34.0M | $4.6M | $0.05 |
Analyst Ratings
Consensus
Buy
Target (Consensus)
$10.50
Target (Median)
$10.50
Target Range
$10.00 - $11.00
Trading Activity
Insider Trades
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Biotechnology
Country
US
Exchange
—
Beta
2.06
Niagen Bioscience Inc operates as a biotechnology enterprise with a core focus on promoting healthy aging. This company is also renowned for its pioneering research into nicotinamide adenine dinucleotide.